Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-26T03:46:38.229Z Has data issue: false hasContentIssue false
  • English
  • Français

Commentary on Robert Whitaker's viewpoint

Published online by Cambridge University Press:  26 October 2020

Jari Tiihonen Open the ORCID record for Jari Tiihonen [Opens in a new window] ,
Heidi Taipale Open the ORCID record for Heidi Taipale [Opens in a new window]  and
Christoph U. Correll Open the ORCID record for Christoph U. Correll [Opens in a new window]
Jari Tiihonen*
Affiliation:
Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Niuvankuja 65, FI-70240Kuopio, Finland Department of Clinical Neuroscience, Karolinska Institutet, Tomtebodavägen 18A, 5th floor, SE-171 77Stockholm, Sweden Stockholm County Council, Stockholm Health Care Services, Norra Stationsgatan 69, SE-113 64Stockholm, Sweden
Heidi Taipale
Affiliation:
Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Niuvankuja 65, FI-70240Kuopio, Finland Department of Clinical Neuroscience, Karolinska Institutet, Tomtebodavägen 18A, 5th floor, SE-171 77Stockholm, Sweden School of Pharmacy, University of Eastern Finland, PO Box 1627, SE-70211Kuopio, Finland
Christoph U. Correll
Affiliation:
Division of Psychiatry Research, The Zucker Hillside Hospital, 75-59 263rd St, Glen Oaks, NY11004, USA Department of Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine, Hempstead, NY11550, USA The Feinstein Institute for Medical Research, Manhasset, NY11030, USA Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany
*
Author for correspondence: Jari Tiihonen, E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Invited Commentary
Information
Psychological Medicine , Volume 50 , Issue 16 , December 2020 , pp. 2653 - 2654
Check for updates
Copyright
Copyright © The Author(s), 2020. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Baandrup, L., Gasse, C., Jensen, V. D., Glenthoj, B. Y., Nordentoft, M., Lublin, H., … Mortensen, P. B. (2010). Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: A population-based nested case-control study. The Journal of Clinical Psychiatry, 71(2), 103–108. doi: 10.4088/JCP.08m04818yelCrossRefGoogle ScholarPubMed
Crump, C., Winkleby, M. A., Sundquist, K., & Sundquist, J. (2013). Comorbidities and mortality in persons with schizophrenia: A Swedish national cohort study. The American Journal of Psychiatry, 170(3), 324–333. doi: 10.1176/appi.ajp.2012.12050599CrossRefGoogle ScholarPubMed
Khan, A., Faucett, J., Morrison, S., & Brown, W. A. (2013). Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit/hyperactivity disorder participating in psychopharmacology clinical trials. JAMA Psychiatry, 70(10), 1091–1099. doi: 10.1001/jamapsychiatry.2013.149CrossRefGoogle ScholarPubMed
Kiviniemi, M., Suvisaari, J., Koivumaa-Honkanen, H., Häkkinen, U., Isohanni, M., & Hakko, H. (2013). Antipsychotics and mortality in first-onset schizophrenia: Prospective Finnish register study with 5-year follow-up. Schizophrenia Research, 150(1), 274–280. doi: 10.1016/j.schres.2013.07.043CrossRefGoogle ScholarPubMed
Schneider-Thoma, J., Efthimiou, O., Huhn, M., Krause, M., Reichelt, L., Röder, H., … Leucht, S. (2018). Second-generation antipsychotic drugs and short-term mortality: A systematic review and meta-analysis of placebo-controlled randomised controlled trials. Lancet Psychiatry, 5(8), 653–663. doi: 10.1016/S2215-0366(18)30177-9CrossRefGoogle ScholarPubMed
Taipale, H., Tanskanen, A., Mehtälä, J., Vattulainen, J., Correll, C. U., & Tiihonen, J. (2020). 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry, 19(1), 61–68. doi: 10.1002/wps.20699CrossRefGoogle Scholar
Tiihonen, J., Mittendorfer-Rutz, E., Torniainen, M., Alexanderson, K., & Tanskanen, A. (2016). Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: An observational follow-up study. American Journal of Psychiatry, 173(6), 600–606. doi: 10.1176/appi.ajp.2015.15050618CrossRefGoogle Scholar
Tiihonen, J., Suokas, J. T., Suvisaari, J. M., Haukka, J., & Korhonen, P. (2012). Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Archives of General Psychiatry, 69(5), 476–483. doi: 10.1001/archgenpsychiatry.2011.1532CrossRefGoogle ScholarPubMed
Torniainen, M., Mittendorfer-Rutz, E., Tanskanen, A., Björkenstam, C., Suvisaari, J., Alexanderson, K., & Tiihonen, J. (2015). Antipsychotic treatment and mortality in schizophrenia. Schizophrenia Bulletin, 41(3), 656–663. doi: 10.1093/schbul/sbu164CrossRefGoogle Scholar
Vermeulen, J., van Rooijen, G., Doedens, P., Numminen, E., van Tricht, M., & de Haan, L. (2017). Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis. Psychological Medicine, 47(13), 2217–2228. doi: 10.1017/S0033291717000873CrossRefGoogle ScholarPubMed
Whitaker, R. (2020). Viewpoint: Do antipsychotics protect against early death? A critical view. Psychological Medicine, 1–10. doi: 10.1017/S003329172000358XGoogle Scholar